ArticleBlood cancer journal2013
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.
Article in Blood cancer journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 63 citations in OpenAlex.
- Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.Nature communications · 2017Trial
- Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.Leukemia · 2022Article
- Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.International journal of hematology · 2022Article
- Bayesian graphical models for modern biological applications.Statistical methods & applications · 2022Review
- SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma.Frontiers in pharmacology · 2022Article
- Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.Targeted oncology · 2021Article
- Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma.Oncotarget · 2020Article
- Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.International journal of molecular sciences · 2020Review
- Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.BMC cancer · 2020Article
- NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains.Nature communications · 2019Article
- Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.Biomolecules · 2019Article
- Bayesian Graphical Regression.Journal of the American Statistical Association · 2019Article
- PLATYPUS: A Multiple-View Learning Predictive Framework for Cancer Drug Sensitivity Prediction.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2019Article
- Article
- Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.International journal of molecular sciences · 2018Article
- Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma HarboringJCO precision oncology · 2018Article
- Loss ofCancer research · 2017Article
- Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery.The pharmacogenomics journal · 2017Article
- Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.Oncotarget · 2017Article
- High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Ras/Raf/MEK/extracellular signal regulated kinase (ERK) (Ras/mitogen-activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many fundamental biological processes, including cellular proliferation, survival, angiogenesis and migration. Aberrant signalling through the Ras/MAPK cascade is common in a wide array of malignancies, including multiple myeloma (MM), making it an appealing candidate for the development of novel targeted therapies. In this review, we explore our current understanding of the Ras/MAPK pathway and its role in MM. Additionally, we summarise the current status of small molecule inhibitors of MEK under clinical evaluation, and discuss future approaches required to optimise their use.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.